Gamco Investors INC. ET AL Purchases 1,300 Shares of Davita Inc (DVA)
Gamco Investors INC. ET AL boosted its position in Davita Inc (NYSE:DVA) by 4.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 32,856 shares of the company’s stock after acquiring an additional 1,300 shares during the period. Gamco Investors INC. ET AL’s holdings in Davita were worth $1,784,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in DVA. CSat Investment Advisory L.P. raised its stake in shares of Davita by 61.8% in the fourth quarter. CSat Investment Advisory L.P. now owns 581 shares of the company’s stock worth $30,000 after purchasing an additional 222 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in shares of Davita in the fourth quarter worth approximately $34,000. Quadrant Capital Group LLC raised its stake in shares of Davita by 2,481.1% in the first quarter. Quadrant Capital Group LLC now owns 955 shares of the company’s stock worth $50,000 after purchasing an additional 918 shares during the last quarter. First Interstate Bank purchased a new stake in shares of Davita in the first quarter worth approximately $65,000. Finally, Fort L.P. purchased a new stake in shares of Davita in the fourth quarter worth approximately $76,000. Institutional investors and hedge funds own 90.78% of the company’s stock.
Shares of Davita stock opened at $51.24 on Wednesday. The company has a market capitalization of $8.52 billion, a PE ratio of 14.35, a P/E/G ratio of 0.54 and a beta of 1.28. Davita Inc has a 52 week low of $48.25 and a 52 week high of $79.11. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.12 and a quick ratio of 1.11.
Several analysts have recently commented on DVA shares. Zacks Investment Research raised Davita from a “sell” rating to a “hold” rating in a research note on Thursday, February 14th. Robert W. Baird lowered their price objective on Davita from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, February 15th. They noted that the move was a valuation call. SunTrust Banks reissued a “hold” rating on shares of Davita in a research note on Wednesday, February 20th. Finally, Deutsche Bank lowered their price objective on Davita from $68.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. Davita has an average rating of “Hold” and a consensus target price of $67.78.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: What is the Federal Reserve?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.